Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OLIGAMI: Metastasis-Directed Therapy for Oligometastatic Breast Cancer
NCT06135714Phase 3Recruiting
- Sponsor
- Tokyo Medical and Dental University
- Start
- Nov 2023
- Primary completion
- Nov 2029
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer and oligometastatic disease (OMD) (2 arms), sponsored by Tokyo Medical and Dental University. Primary endpoint: Overall survival after second registration at 5 years. Started Nov 2023; status: recruiting.
02
Conditions
breast canceroligometastatic disease (OMD)
Beyond the preview
Go deeper on NCT06135714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06135714.